Siegfried

Siegfried Opens New Drug Substances R&D Center in Evionnaz

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

Siegfried to Buy Early-Phase CDMO Site from Curia

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.

Siegfried to Acquire Early-Phase CDMO in US

Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.

Wolfgang Wienand to Join Lonza as New CEO

Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional responsibility of interim CEO in October 2023 while the search for a permanent CEO took place.

Siegfried Announces Changes in Senior Management Team

Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.

Expanding Expertise in Highly-Potent APIs

After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.

Increasing the Sustainability of API Production

For Siegfried, sustainability is much more than a phrase with a green coating. The term, which encompasses social and economic criteria in addition to ecological aspects, is one of five central corporate values. One of the biggest levers for reducing energy and resource consumption in the pharma supply chain lies in the efficient production of active ingredients and pharmaceuticals. The company therefore works consistently on optimizing its processes.

Small Substances with Big Effects

The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.

Opportunities and Limits of Sustainability

The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.

Special Issue: Swiss CDMO Siegfried Celebrates 150th Anniversary

There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.

Sustainability – The Many Facets of Action

Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?

Siegfried Demonstrates Biologics Expertise in Hameln

The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.

"We Want to Be a Big Fish"

The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.

Siegfried Takes Majority Stake in Dinamiqs

Swiss CDMO Siegfried has acquired a 95% stake in Dinamiqs, a compatriot biotech focused on developing and manufacturing viral vectors for cell and gene therapies.

Siegfried Breaks Ground for Global R&D Center

Swiss-based, globally oriented CDMO Siegfried has broken ground or its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland, which the company describes as a “key pillar” in its related network.

Flow Chemistry

Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.

Expert Statement: Christophe Girard, Siegfried

Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.

Siegfried to Buy Two Novartis Sites in Spain

Swiss CDMO Siegfried has signed a binding agreement with compatriot Novartis to acquire two pharmaceutical manufacturing sites in Spain. The Zofingen-based group said the buy will “significantly enhance” its global production network in terms of capacity and technological capabilities and will allow it to reach a critical size in finished dosage forms, thus creating further potential for profitable growth.

Innovative Chemistry Between Mountains and Lakes

Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.

Experts Statements: Marianne Späne, Siegfried

Trend Barometer of Specialty Chemicals Industry

Opportunities for Western CDMOs in China

M&A in Pharma and CRO/CMO Industry

A Wide Spectrum of Contract Services

Wolfgang Wienand to Succeed Rudolf Hanko as CEO of Siegfried

Experts Statements: Dr. René Imwinkelried, Siegfried

The Winning Formula

The Winning Formula

Addressing The Pharma Innovation Gap

The New Globalism

Siegfried Ready to Take Over BASF Sites

German Antitrust Authority Allows BASF-Siegfried Deal

BASF to Sell Custom Synthesis Business to Siegfried

Siegfried Acquires Hameln Pharma

CPhI 2014 Experts Statements:Dr. Rudolf Hanko, CEO, Siegfried